Online inquiry

IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13765MR)

This product GTTS-WQ13765MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Sarcopenia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13765MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1812MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ9838MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JTX-2011
GTTS-WQ14332MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RG7414
GTTS-WQ8214MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA hLIV22
GTTS-WQ12207MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ897MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-181
GTTS-WQ4718MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BOS161721
GTTS-WQ14379MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA r-hTBP-1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW